Fig. 3From: Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancersPharmacogenomic screening of CYP450 enzymes and drug transporters for TKIs could help in stratifying the population into various categories of drug responders. Created with BioRender.com (Agreement number: II237SHPD4). Abbreviations: PGx: Pharmacogenomics; TKI: Tyrosine kinase inhibitors; BCRP: Breast cancer resistant protein; P-gp: Permeability glycoprotein; IM: Intermediate metabolizers; PM: Poor metabolizers; EM: Extensive metabolizers; UM: Ultra rapid metabolizers; DDI: Drug-drug interactionBack to article page